Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications primarily in infectious diseases, womens health, and gastrointestinal diseases. The company was founded in 1979 and is based in San Diego, California.
QDEL Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Quidel Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Quidel Corp ranked in the 68th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. In terms of the factors that were most noteworthy in this DCF analysis for QDEL, they are:
In the past 5.31 years, Quidel Corp has a compound free cash flow growth rate of 0.71%; that's higher than 86.21% of free cash flow generating stocks in the Healthcare sector.
97% of the company's capital comes from equity, which is greater than 91.49% of stocks in our cash flow based forecasting set.
The business' balance sheet reveals debt to be 3% of the company's capital (with equity being the remaining amount). Approximately only 8.47% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Quidel Corp? See ABBV, FMS, RSCF, SEM, and AMN.